TY - JOUR T1 - Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer JF - Anticancer Research JO - Anticancer Res SP - 1417 LP - 1420 VL - 31 IS - 4 AU - DAVID R. FOGELMAN AU - ROBERT A. WOLFF AU - SCOTT KOPETZ AU - MILIND JAVLE AU - CHARLES BRADLEY AU - ISABEL MOK AU - FERNANDO CABANILLAS AU - JAMES L. ABBRUZZESE Y1 - 2011/04/01 UR - http://ar.iiarjournals.org/content/31/4/1417.abstract N2 - Pancreatic cancer is an aggressive, frequently fatal malignancy that strikes 37,000 patients annually in the U.S.A. It is poorly responsive to standard chemotherapies such as gemcitabine. Approximately 5-10% of pancreatic cancer occurs in the setting of a BRCA2 mutation. Breast and ovarian carcinomas that harbor BRCA2 mutations are susceptible to the effects of an emerging class of targeted agents, namely, poly(ADP-ribose) polymerase (PARP) inhibitors. This report describes the case of a patient with a germline BRCA2 mutation and an associated pancreatic cancer treated with iniparib (BSI-201), a PARP inhibitor, who demonstrated a complete pathologic response to this agent. This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer. ER -